Trial NCT03969420

View at ClinicalTrials.gov 
Org. Study IDs: TPI-ALV-202

Last trial update was posted on 2023-11-09

MeSH Interventions

Alvocidib Cytarabine

MeSH Conditions

Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute

Other Conditions

Acute Myeloid Leukemia (AML)

Stopping Reasons

Business decision to terminate the development of alvocidib program on 17 November 2020. Patients permitted on treatment until April 22, 2021. The last end-of-treatment follow-up completed on May 14, 2021.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID